STXS
AMEXStereotaxis Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$1.29-0.61 (-32.20%)
2026-04-212026-07-24
News · 26 weeks34+17%
2026-02-012026-07-26
Mix1990d
- SEC Filings7(37%)
- Insider6(32%)
- Other3(16%)
- Earnings2(11%)
- Leadership1(5%)
Latest news
25 items- PRStereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis second quarter 2026 financial results conference call When:Tuesday, August 11, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (In
- PRUniversity of Szeged Pioneers First Robotic Cardiology Program in HungaryFirst Robotic Magnetic Navigation system installed in HungaryUniversity of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using precision of robotics ST. LOUIS, July 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of the first advanced robotic cardiology program in Hungary at the University of Szeged in Szeged, Hungary. The Cardiology Center (Szent-Györgyi Albert Clinical Center) at the University of Szeged is the first hospital in Hungary to establish a heart rhythm progr
- SECStereotaxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form S-3 filed by Stereotaxis Inc.S-3 - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form S-3 filed by Stereotaxis Inc.S-3 - Stereotaxis, Inc. (0001289340) (Filer)
- SECStereotaxis Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Stereotaxis, Inc. (0001289340) (Filer)
- PRStereotaxis Completes Acquisition of RobocathST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions. Robocath will now be fully integrated into Stereotaxis, combining complementary technologies and expertise to accelerate the development of next-generation robotic solutions for electrophysiology, interventional cardiology, and neurointerventions. The combined platform strengthens Stereotaxis’s position as the leader in robotic t
- INSIDERDirector Shamir Nachum was granted 43,103 shares, increasing direct ownership by 32% to 179,327 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Benfer David was granted 43,103 shares, increasing direct ownership by 8% to 558,975 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Levin Ross B was granted 43,103 shares, increasing direct ownership by 7% to 621,248 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Menawat Arun Swarup was granted 43,103 shares, increasing direct ownership by 4% to 1,035,560 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Fischel Nathan was granted 43,103 shares, increasing direct ownership by 6% to 720,775 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- INSIDERDirector Curet Myriam was granted 43,103 shares, increasing direct ownership by 11% to 435,161 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
- SECSEC Form SD filed by Stereotaxis Inc.SD - Stereotaxis, Inc. (0001289340) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stereotaxis Inc.SCHEDULE 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
- SECStereotaxis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form 10-Q filed by Stereotaxis Inc.10-Q - Stereotaxis, Inc. (0001289340) (Filer)
- SECStereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Stereotaxis, Inc. (0001289340) (Filer)
- PRStereotaxis Reports 2026 First Quarter Financial Results & Business UpdatesProprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as EuropeSynchrony digital operating room system received U.S. FDA clearance in April and initial orders and shipments are ongoingDefinitive agreement to acquire Robocath creates a leading robotic platform, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for the full spectrum of endovascular procedures ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today repo
- PRStereotaxis Announces First MAGiC Procedures in the United StatesST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated using MAGiC™. MAGiC, Stereotaxis' proprietary robotically-navigated magnetic interventional cardiac ablation catheter, recently received Food & Drug Administration PMA approval. It is the first ablation catheter specifically approved to treat arrhythmia in patients with complex congenital heart disease. Dr. Nathan McConkey, Cardiac Electrophysiologist at Oregon Health & Science University, performed the first MAGiC procedure in the United States o
- PRStereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What: Stereotaxis first quarter 2026 financial results conference call When: Tuesday, May 12, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number: To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (Internati
- SECStereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Stereotaxis, Inc. (0001289340) (Filer)
- PRStereotaxis Announces Definitive Agreement to Acquire RobocathST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions. This acquisition significantly strengthens Stereotaxis' position as a leading platform for the full spectrum of endovascular procedures, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for electrophysiology, interventional cardiology and neurointerventions. "Robocath
- INSIDERSEC Form 4 filed by Peery Kimberly R.4 - Stereotaxis, Inc. (0001289340) (Issuer)
- PRStereotaxis Announces FDA Clearance and Launch of Synchrony SystemST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony's slim and stunning 55" 4K ultra-high-definition display consolidates the viewing and control of all disparate systems in the lab, offering an enhanced procedure experience with custom layouts, streamlined workflows, an intuitive user interface, and a decluttered environment. Synchrony digitizes the video streams with full
STXS FAQ
6 questionsWhat does Stereotaxis Inc. do?
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage...Where does STXS stock trade?
Stereotaxis Inc. (STXS) is listed on AMEX.What sector and industry is STXS in?
Stereotaxis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about STXS?
Stereotaxis Inc. has had 6 recent analyst actions on file. The most recent action was from Citizens JMP: Mkt Outperform with a $400.00 price target on 2025-12-16. Recent price targets range from $400.00 to $1300.00.What companies are similar to STXS?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare STXS side-by-side with any of them on Quantisnow.How can I track STXS on Quantisnow?
Quantisnow aggregates Stereotaxis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STXS to receive live email and push alerts on every new disclosure.